Companies covered: SCYNEXIS, Inc. (NASDAQ:SCYX), Cidara Therapeutics Inc. (NASDAQ:CDTX), Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), ContraFect Corporation (NASDAQ:CFRX), Veru Inc. (NASDAQ:VERU), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), Vaxart (NASDAQ:VXRT), NLS Pharmaceutics AG (NASDAQ:NLSP), Medicenna Therapeutics Corp. (NASDAQ:MDNA), Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Dermata Therapeutics Inc. (NASDAQ:DRMA), Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), AstraZeneca PLC (NASDAQ:AZN), Chinook Therapeutics Inc. (NASDAQ:KDNY), Autolus Therapeutics PLC (NASDAQ:AUTL), Blackstone Inc. (NYSE:BX), Amgen Inc. (NASDAQ:AMGN), Dynavax Technologies Corporation (NASDAQ:DVAX), AbbVie Inc. (NYSE:ABBV), Pfizer, Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Theseus Pharmaceuticals Inc. (NASDAQ:THRX), 2Seventy Bio Inc. (NASDAQ:TSVT), bluebird bio, Inc. (NASDAQ:BLUE), Cogent Biosciences Inc. (NASDAQ:COGT), Chimerix, Inc. (NASDAQ:CMRX), Deciphera Pharmaceuticals (NASDAQ:DCPH), Bristol-Myers Squibb Company (NYSE:BMY), iTeos Therapeutics Inc. (NASDAQ:ITOS), Roche Holdings Ltd. (ADR) (OTCMKTS:RHHBY), GlaxoSmithKline PLC (NYSE:GSK), Zogenix, Inc. (NASDAQ:ZGNX), Argenx SE (ADR) (NASDAQ:ARGX), Abivax (OTCMKTS:AAVXF), Angion Biomedica Corp. (NASDAQ:ANGN), Biovaxys Technology Corp. (OTCMKTS:BVAXF), Codex DNA, Inc. (NASDAQ:DNAY), COMPASS Pathways PLC (NASDAQ:CMPS), GeNeuro SA (OTCMKTS:GNRRF), GenSight Biologics SA (OTCMKTS:GSGTF), Jaguar Health Inc. (NASDAQ:JAGX), Vyant Bio Inc. (NASDAQ:VYNT)
